GNFT
- Genfit S.A.
()
Overview
Company Summary
Genfit S.A. (GNFT) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for patients with liver diseases and other metabolic disorders. The company is primarily engaged in the research and development of personalized medicines to address unmet medical needs in areas such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other chronic liver diseases.
Genfit is dedicated to tackling liver diseases, which are a significant global health concern, with limited treatment options. The company's approach involves developing therapeutics that target specific biological pathways and mechanisms underlying these diseases.
One of Genfit's most prominent drug candidates is Elafibranor, an oral medication under investigation for the treatment of NASH. NASH is a severe and progressive form of non-alcoholic fatty liver disease (NAFLD) that can lead to liver cirrhosis, hepatocellular carcinoma, and liver failure. Elafibranor aims to reduce liver inflammation and improve metabolic parameters associated with the condition.
In addition to its expertise in liver diseases, Genfit is also involved in the development of diagnostic tools and methods to identify patients who may respond better to their treatments. Their goal is to provide physicians with insightful tools for patient stratification and personalized treatment decisions.
Overall, Genfit S.A. is dedicated to advancing the understanding, research, and development of innovative therapies for liver diseases, aiming to improve the lives of patients suffering from these conditions and make a meaningful impact in the field of hepatology.